Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

BACKGROUND. The CHER-LOB randomized phase II study showed that the combination of lapatinib and trastuzumab plus chemotherapy increases the pathologic complete remission (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. A biomarker program was prospectively planned to ident...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Guarneri, Valentina, Dieci, Maria Vittoria, Frassoldati, Antonio, Maiorana, Antonino, Ficarra, Guido, Bettelli, Stefania, Tagliafico, Enrico, Bicciato, Silvio, Generali, Daniele Giulio, Cagossi, Katia, Bisagni, Giancarlo, Sarti, Samanta, Musolino, Antonino, Ellis, Catherine, Crescenzo, Rocco, Conte, PierFranco
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2015
Témata:
Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4571802/
https://ncbi.nlm.nih.gov/pubmed/26245675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0138
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky